Effects of L-arginine Supplementation in Adults With Moderate to Severe Asthma
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Nitric oxide is an important marker of airway inflammation in asthma. Nitric oxide may have a
protective role in patients with moderate to severe asthma. The investigators believe that a
natural amino acid, L-arginine, that augments nitric oxide levels can decrease asthma
exacerbations and improve the asthma care of moderate to severe asthma patients.
This study is a randomized, placebo controlled trial in which subjects will receive either 3
months of L-arginine supplementation or a placebo. The investigators will monitor subjects'
symptoms, the number of asthma exacerbations, and lung function. In addition, we will draw
blood, obtain induced sputum samples and measure exhaled breath nitric oxide levels at each
monthly visit.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, Davis
Collaborators:
National Center for Research Resources (NCRR) National Institutes of Health (NIH)